Shanghai Antengene Corporation

Company snapshot

Shanghai Antengene Corporation is a pharma organization headquartered in SAINT-LAURENT, CN. Primary therapeutic focus areas include Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (NMIBC), Superficial Bladder Cancer. NovaPharmaNews links 3 clinical program(s), 2 drug profile(s), and 53 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2), phase 1 (1).

• 3 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 53 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Shanghai Antengene Corporation. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Shanghai Antengene Corporation.

1. Jun 8, 2026 Clinical update

   EG-70-101 — Phase 2

2. Jun 8, 2026 Clinical update

   EG-70 (phase 1) — Phase 2

3. Jun 5, 2026 Clinical update

   ATG-010 and ATG-008 — Phase 1

4. Sep 23, 2025 Patent grant

   Ectonucleotidase inhibitors and methods of use thereof

5. Sep 16, 2025 Patent grant

   Compositions comprising bacterially derived minicells and methods of using the same

View all clinical trial activity →

• What is Shanghai Antengene Corporation?

  Shanghai Antengene Corporation is a pharma organization headquartered in SAINT-LAURENT, CN. Primary therapeutic focus areas include Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (NMIBC), Superficial Bladder Cancer. NovaPharmaNews links 3 cl

• Is Shanghai Antengene Corporation publicly traded?

  Shanghai Antengene Corporation appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai Antengene Corporation develop or market?

  We link 8 drug profile(s) where Shanghai Antengene Corporation is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/engene-therapeutics#company-drugs.

• What are the latest developments for Shanghai Antengene Corporation?

  In the last 12 months our linked public records show 3 trial program update(s) and 4 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai Antengene Corporation focus on?

  Shanghai Antengene Corporation focuses on Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (NMIBC), Superficial Bladder Cancer based on our analysis of their pipeline programs and drug development activities.